CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On
Capricor Therapeutics (CAPR) stock has surged nearly 30% this week due to investor anticipation of a key February FDA filing for its Duchenne Muscular Dystrophy (DMD) therapy, Deramiocel. The FDA requested the full clinical study report of its Phase 3 Hope-3 trial, with the submission expected this month, addressing previous concerns without requiring new trials. Analysts have responded positively to the strong Phase 3 data, raising price targets and maintaining "Buy" ratings, with some projecting over $1 billion in sales by 2030.
GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR
GSA Capital Partners LLP has initiated a new investment in Capricor Therapeutics, purchasing 215,675 shares worth approximately $1.56 million, representing 0.47% ownership. This move aligns with a largely positive analyst sentiment, given the company's clinical-stage biotechnology focus on cell and exosome-based therapies. Capricor Therapeutics currently holds a "Moderate Buy" consensus rating with an average target price of $40.82 from analysts.
(CAPR) Price Dynamics and Execution-Aware Positioning
This article analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR) stock, highlighting a mid-channel oscillation pattern and an exceptional 119.6:1 risk-reward short setup. It details AI-generated institutional trading strategies including long position, momentum breakout, and short risk-hedging strategies, alongside multi-timeframe signal analysis for near, mid, and long-term outlooks. The analysis suggests positive near-term sentiment may counter a mid-term weak bias within a long-term strength context.
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing
Capricor Therapeutics (CAPR) recently filed a shelf registration for approximately US$64.9 million in common stock, giving it flexibility for future equity issuance. Despite a substantial 3-year total shareholder return, recent share price momentum has cooled, prompting a re-evaluation of its valuation. Analysts are divided, with price targets ranging from $12.0 to $29.0, while Simply Wall St's analysis suggests a fair value of $50.80, indicating the stock might be significantly undervalued.
Johnson Fistel, PLLP Investigates Claims on Behalf of
Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by officers and directors of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO). The investigations focus on alleged misconduct, including price-fixing, undisclosed manufacturing issues, misleading statements regarding drug prospects, and unsustainable financial practices. Shareholders who have held shares continuously since specified dates may be eligible to seek corporate governance reforms and other remedies.
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing
Capricor Therapeutics (CAPR) has filed a shelf registration for approximately US$64.9 million, allowing it to issue equity over time. This move comes after significant share price returns and a current undervaluation narrative, yet the company faces ongoing net losses. The article explores the valuation implications of this filing, highlighting a wide range between analyst price targets and Simply Wall St's intrinsic value estimates, and discusses the risks associated with future funding and regulatory setbacks.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received a consensus "Moderate Buy" rating from analysts, with nine out of ten firms issuing buy recommendations and an average one-year price target of $40.82. Several brokers, including HC Wainwright and Oppenheimer, recently raised their price targets significantly. The clinical-stage biotech company, developing therapies for conditions like Duchenne muscular dystrophy, trades around $22.61, maintains a market capitalization of approximately $1.03 billion, and institutional investors own about 21.7% of its stock.
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)?
Capricor Therapeutics (CAPR) received a regulatory update on its Biologics License Application for Deramiocel, with the FDA requesting the full Phase 3 HOPE-3 clinical study report but no new trials. This shifts the investment focus from clinical risk to regulatory and timing risk, as the company plans to submit the report in February 2026. Despite this positive development regarding new trials, Capricor remains unprofitable, dependent on external funding, and vulnerable to share price volatility.
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving Average - Should You Sell?
Capricor Therapeutics (NASDAQ:CAPR) shares recently crossed above their 50-day moving average, trading as high as $23.75. Analysts have a "Moderate Buy" consensus rating with an average target price of $40.82, and multiple firms have significantly increased their price objectives for the stock. Despite a $1.08 billion market cap, the company remains unprofitable, focusing on its lead candidate CAP-1002 for Duchenne muscular dystrophy and cardiac indications.
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)?
Capricor Therapeutics received a regulatory update from the FDA regarding its Biologics License Application for Deramiocel, with the agency requesting the full Phase 3 HOPE-3 clinical study report but no new trials or patient data. This shifts the investment focus from clinical risk to regulatory and timing risk for Capricor. The company plans to submit the HOPE-3 report in February 2026, making regulatory interpretation of existing data a key near-term catalyst.
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA
Capricor Therapeutics (CAPR) is seeing increased interest after the FDA requested the full Phase 3 HOPE-3 clinical study report for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, without requiring new trials. The stock has experienced significant returns, and while analysts have a consensus price target of $20.6, Simply Wall St's analysis suggests a fair value of $44.56, indicating it may still be undervalued despite recent gains. Investors are encouraged to consider the regulatory pathway and potential for dilution.
(CAPR) as a Liquidity Pulse for Institutional Tactics
Capricor Therapeutics Inc. (CAPR) is showing weak near and mid-term sentiment, despite a strong long-term outlook. Predictive AI analysis indicates a potential 37.2% downside with a low-risk short setup. The article details three institutional trading strategies tailored to various risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy.
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA
Capricor Therapeutics (CAPR) shares are gaining attention as the FDA advances its review of Deramiocel for Duchenne muscular dystrophy, requesting the full Phase 3 HOPE-3 study report without requiring new trials. Despite significant recent share price appreciation, the stock is currently trading at US$23.62 against an analyst target of US$50.80, with a perceived intrinsic discount of about 91%. The article highlights a fair value narrative of $44.56, but cautions investors about potential regulatory setbacks or dilution risks.
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)?
Capricor Therapeutics recently received a request from the FDA for the full clinical study report and supporting data for Deramiocel's Phase 3 HOPE-3 trial, without demanding new clinical trials. This request, following a prior Complete Response Letter, means the company plans to submit the report in February 2026, potentially clarifying the regulatory path for their Duchenne muscular dystrophy treatment. Investors are now focused on this submission and the subsequent FDA review, while also considering the company's financial burn rate and differing fair value estimates for the stock.
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)?
Capricor Therapeutics (CAPR) announced that the FDA requested the full clinical study report and supporting data for Deramiocel's Phase 3 HOPE-3 trial in Duchenne muscular dystrophy, without demanding new trials. This request, expected to be fulfilled by February 2026, aims to clarify the regulatory path for their single asset, Deramiocel, which has multiple expedited designations. Investors will closely watch the submission and potential PDUFA date as the company remains loss-making and dependent on this therapy's approval.
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop
Capricor Therapeutics plans to submit the full HOPE-3 clinical study report to the FDA in February, aiming to address concerns raised after a previous rejection and advance its Duchenne muscular dystrophy treatment, Deramiocel. Despite a recent 2% stock drop, the company has seen significant gains over the past year, reflecting investor optimism for the drug's approval following positive HOPE-3 trial results showing improved muscle and heart function. Analyst price targets suggest a substantial increase in CAPR's stock value, with several firms upgrading their ratings based on the strong clinical data.
FDA Requests Capricor To Submit HOPE-3 Clinical Study Report For Deramiocel BLA Review
Capricor Therapeutics announced that the FDA has requested the full clinical study report from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy. This request follows the FDA's review of topline data and does not ask for additional trials or patient data. Capricor expects to submit the report in February 2026 to address a prior Complete Response Letter and support continued FDA review.
Capricor to submit HOPE-3 data to FDA for DMD therapy review
Capricor Therapeutics announced it will submit the full clinical study report for its Phase 3 HOPE-3 trial to the FDA in February 2026 as requested by regulators. The FDA did not ask for additional clinical studies or new patient data, and Capricor expects this submission to address previous issues and support continued review of its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. The company's shares have surged by 253% in the past six months, indicating strong market interest despite volatility.
Capricor Therapeutics Inc. Provides Regulatory Update on Deramiocel BLA Submission Following FDA Request for HOPE-3 Clinical Study Report
Capricor Therapeutics announced that the FDA has requested the full clinical study report (CSR) for its HOPE-3 trial as part of the Biologics License Application (BLA) review for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The company plans to submit these materials in February 2026 to address issues from a previous Complete Response Letter and facilitate continued review, including the assignment of a new PDUFA target action date. CEO Linda Marbán expressed confidence in the HOPE-3 data, which showed significant improvements in muscle function for DMD patients.
FDA asks for full HOPE-3 data on DMD cell therapy, no new trials
Capricor Therapeutics announced that the FDA has requested the full HOPE-3 clinical study report (CSR) for its Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD). The FDA did not ask for additional clinical studies or new patient data. Capricor plans to submit the CSR in February 2026 to address a July 2025 Complete Response Letter and expects a new PDUFA target action date to be assigned.
Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating and a $62.00 price target for Capricor Therapeutics (NASDAQ:CAPR) following positive results from its HOPE-3 Phase 3 clinical trial for Duchenne muscular dystrophy treatment, deramiocel. The firm expects Capricor to submit complete trial data to the FDA in mid-February, with a filing acceptance decision anticipated 30 days later, potentially driving stock appreciation. Despite a 232% price return over six months, the stock operates with moderate debt and is not expected to be profitable this year.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Pomerantz LLP is investigating potential claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) following a significant stock price drop. This investigation was launched after the FDA confirmed its intent to hold an advisory committee meeting regarding Capricor's Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The news led to a 29.13% fall in Capricor's stock price.
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $62
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Buy rating for Capricor Therapeutics (CAPR.US) and significantly increased the target price from $22 to $62. The analyst, according to TipRanks data, boasts a 48.8% success rate and an average return of 29.1% over the past year. This report emphasizes that the information is for educational purposes only and does not constitute investment advice.
Cantor Fitzgerald reiterates Overweight rating on Capricor stock By Investing.com
Cantor Fitzgerald has reiterated its Overweight rating and a $62.00 price target for Capricor Therapeutics (NASDAQ:CAPR), indicating significant upside potential from its current trading price. Despite positive clinical data, the market still prices in regulatory risk, leading to caution and high stock volatility. Cantor Fitzgerald believes the market's estimated 25% probability of success is too low for a company with positive Phase 3 data and anticipates potential stock increases leading up to a PDUFA date.
Cantor Fitzgerald reiterates Overweight rating on Capricor stock
Cantor Fitzgerald has reaffirmed its Overweight rating and $62 price target for Capricor Therapeutics (NASDAQ:CAPR), citing significant upside potential despite current market caution regarding regulatory risks. The firm believes the market is underestimating the probability of success for Capricor's therapeutic given its positive Phase 3 data. This positive outlook is supported by other analysts like Piper Sandler and Oppenheimer, who have also raised price targets following successful Phase III HOPE-3 trial results for Duchenne muscular dystrophy.
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals
Capricor Therapeutics (CAPR) recently reported successful Phase 3 trial results for deramiocel and commercialization deals with Nippon Shinyaku, including potential milestone payments up to US$1.5 billion. Despite this success, the stock has seen a recent pullback. Analysts are pegging CAPR as undervalued, with a fair value of US$44.56 per share, due to anticipated accelerated approval, higher margins, and future revenue growth, though this depends on timely approval and strong HOPE-3 outcomes.
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals
Capricor Therapeutics (CAPR) saw its deramiocel Phase 3 trial meet primary and secondary endpoints, leading to commercialization deals with Nippon Shinyaku that could bring up to US$1.5 billion in milestone payments. Despite recent share price cooling, the company is considered undervalued by analysts with a fair value of US$44.56 per share against a current trading price of US$23.84. This valuation anticipates accelerated approval and commercialization due to Capricor's manufacturing readiness and regulatory advancements for rare diseases.
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal
Capricor Therapeutics (CAPR) experienced a 15.8% stock drop despite positive Phase 3 trial results for deramiocel and commercialization agreements with Nippon Shinyaku potentially totaling $1.5 billion. The investment narrative is now centered on regulatory approval for deramiocel, with analysts forecasting significant revenue and earnings growth by 2028, suggesting a substantial upside to its current price. However, regulatory unpredictability remains a key risk influencing the varied fair value estimates from the Simply Wall St Community.
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal
Capricor Therapeutics' stock fell despite a successful Phase 3 trial for deramiocel and a substantial $1.5 billion commercialization deal with Nippon Shinyaku. The company's future hinges on regulatory approval for deramiocel, with current forecasts predicting significant revenue and earnings growth by 2028 and a fair value suggesting an 87% upside. However, investor sentiment remains cautious due to regulatory uncertainty and the company's reliance on a single lead asset.
(CAPR) Movement as an Input in Quant Signal Sets
This article analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR) using AI-driven quant signals, highlighting conflicting sentiment and elevated downside risk. It provides tactical trading strategies including long, breakout, and short positions with defined entry, target, and stop-loss levels based on multi-timeframe signal analysis. The analysis suggests choppy conditions for CAPR and offers institutional-grade tools for real-time signal access and risk management.
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win
Martin Shkreli, known as "Pharma Bro," rescinded his short position on Capricor Therapeutics after the company's experimental treatment for Duchenne muscular dystrophy (DMD) achieved its primary endpoint. Shkreli had previously predicted the trial would fail, but positive results for CAP-1002 led to a significant surge in Capricor's stock price, prompting him to admit his error. He announced on X that he covered his short and wished the company well.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $40.82. Several brokers recently raised their targets, some as high as $50-$54. The clinical-stage biotech company, focused on cell and exosome therapies, opened at $28.31, with its lead candidate CAP-1002 being evaluated for Duchenne muscular dystrophy and COVID-19-related heart injury.
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen
Wall Street Zen upgraded Capricor Therapeutics (NASDAQ:CAPR) from "sell" to "hold," joining other firms like Oppenheimer, B. Riley, and Maxim that have recently raised price targets or ratings. The consensus for CAPR is now a "Moderate Buy" with an average price target of $40.82. Capricor, a clinical-stage biotech developing cell and exosome therapies for conditions like Duchenne muscular dystrophy, reported quarterly EPS of -$0.54, meeting estimates, with analysts forecasting -$1.21 for the fiscal year.
U.S. consumer confidence ebbed in February
Consumer confidence in the U.S. dipped slightly in February, following a significant rise in January. Despite the dip, consumers' assessments of current business and labor market conditions improved. However, future expectations regarding income, business, and labor market conditions worsened, indicating some uncertainty about the short-term economic outlook.
HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR
HBK Sorce Advisory LLC increased its stake in Capricor Therapeutics (NASDAQ:CAPR) by 33.7%, purchasing an additional 42,951 shares and now owning 170,577 shares valued at $1.14 million. Other institutions like Goldman Sachs and Octagon Capital also built positions, bringing institutional ownership to 21.68%. Analysts have significantly raised price targets, with an average target of $40.82 and a consensus "Moderate Buy" rating for the biotechnology company.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Capricor Therapeutics, Inc. (NASDAQ:CAPR) following two significant drops in its stock price. The investigation concerns statements related to Capricor's Biologics License Application (BLA) for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. Stockholders are encouraged to learn more and assist the investigation.
HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR
HBK Sorce Advisory LLC increased its holdings in Capricor Therapeutics (NASDAQ:CAPR) by 36.6% in the third quarter, bringing its total to 174,277 shares valued at $1.304 million. Other institutional investors also adjusted their positions, resulting in a total institutional ownership of 21.68% for the biotechnology company. Analysts currently rate CAPR as a "Moderate Buy" with an average target price of $40.82, driven by several recent price target upgrades.
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4%
Short interest in Capricor Therapeutics (NASDAQ:CAPR) experienced a significant 69.4% drop in December, falling to 5,029,282 shares as of December 15th. This reduction in short interest indicates a potential decrease in bearish sentiment towards the biotechnology company. Wall Street analysts maintain a broadly bullish outlook, with nine analysts rating CAPR a "Buy" and an average target price of $40.82.
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal
Capricor Therapeutics has seen its share price surge following positive Phase 3 HOPE-3 trial data for Deramiocel in Duchenne muscular dystrophy and a commercialization deal with Nippon Shinyaku. Despite this, the company is still considered undervalued with a fair value of $44.56 against a current $27.81, driven by significantly revised higher revenue growth and net profit margin expectations. The optimistic outlook is, however, conditional on FDA approval and successful management of R&D costs.
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal
Capricor Therapeutics (CAPR) is receiving renewed attention following positive Phase 3 HOPE-3 trial data for Deramiocel and a new commercialization agreement with Nippon Shinyaku. This has led to a significant surge in Capricor's stock price, with analysts now evaluating whether the current valuation fully reflects the drug's market potential. While the company is deemed undervalued by Simply Wall St's narrative valuation, the path to market still faces FDA uncertainties and mounting R&D costs.
Capricor Therapeutics (CAPR) Is Down 8.8% After HOPE-3 Win And Nippon Shinyaku Deal News – Has The Bull Case Changed?
Capricor Therapeutics experienced an 8.8% stock drop despite positive Phase 3 HOPE-3 results for Deramiocel in Duchenne muscular dystrophy and a commercialization deal with Nippon Shinyaku. The company recently completed a $150 million equity offering to fund operations through regulatory review and pre-launch activities. While these developments support a potential approval, investors still face risks from regulatory delays and dilution, which could impact the company's projected future revenues and earnings.
Capricor Therapeutics (CAPR) Is Down 8.8% After HOPE-3 Win And Nippon Shinyaku Deal News – Has The Bull Case Changed?
Capricor Therapeutics (CAPR) saw an 8.8% stock drop despite positive Phase 3 HOPE-3 results for Deramiocel in Duchenne muscular dystrophy and a commercialization deal with Nippon Shinyaku. The company's investment narrative now hinges on clearing remaining FDA hurdles and managing cash burn, with recent equity offerings aiming to bridge funding to commercialization. Investors must weigh the potential for regulatory delays against the significant projected revenue and earnings growth by 2028.
Capricor Therapeutics Announces Community Webinar on Positive HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar on December 17, 2025, to discuss positive topline results from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy (DMD). The webinar aims to inform patients and families about the trial findings and their implications for regulatory discussions with the FDA. This initiative highlights Capricor's commitment to patient engagement and the advancement of Deramiocel as a potential treatment for DMD.
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Capricor Therapeutics and Parent Project Muscular Dystrophy (PPMD) will host a webinar to discuss positive topline results from Capricor's Phase 3 HOPE-3 trial for Deramiocel, its Duchenne muscular dystrophy (DMD) treatment. The webinar on December 17, 2025, will inform patients and families about the findings and their implications for ongoing regulatory discussions with the FDA. Participants are encouraged to submit questions in advance.
CAPR: B. Riley Securities Raises Target Price to $50, Maintains Buy Rating | CAPR Stock News
B. Riley Securities has raised its price target for Capricor Therapeutics (CAPR) from $21.00 to $50.00, reiterating a Buy rating. This adjustment reflects strong analyst confidence, with similar target increases from other firms like Piper Sandler, Oppenheimer, Maxim Group, HC Wainwright & Co., and Roth Capital. Capricor Therapeutics, a clinical-stage biotechnology company developing therapies for Duchenne muscular dystrophy, shows an average analyst target price of $50.80, implying a significant upside from its current price.
Capricor Therapeutics Anticipating Approval of DMD Cell Therapy
Capricor Therapeutics is anticipating federal regulatory approval for its Duchenne muscular dystrophy (DMD) cell therapy, deramiocel, after positive Phase 3 trial results demonstrated significant improvements in skeletal muscle and cardiac function. The company's stock jumped over 370% following the data release, leading to significant fundraising and plans for commercial launch by Fall 2026 for the approximately 20,000 DMD patients in the U.S. Capricor also plans to expand manufacturing capabilities and partner internationally to meet future demand.
Mintz Advises On Capricor Therapeutics’ $150 Million Public Offering
Mintz advised the underwriters for Capricor Therapeutics' $150 million public offering. Piper Sandler and Oppenheimer & Co. were joint-book running managers, and H.C. Wainwright & Co. acted as co-manager. The Mintz capital markets team and other specialists provided legal and intellectual property advice.
Capricor Therapeutics (CAPR): Reassessing Valuation After Positive Phase 3 HOPE-3 Results for Deramiocel
Capricor Therapeutics (CAPR) has reported positive topline Phase 3 HOPE-3 data for its Duchenne muscular dystrophy therapy, Deramiocel, leading to a reassessment of its valuation. While a narrative-driven fair value suggests the stock is undervalued at around $44.56, its balance sheet shows a high price-to-book ratio compared to peers. Investors are now considering whether the stock is undervalued or if Deramiocel's future upside is already priced in after a significant share price run.
Capricor Therapeutics (CAPR): Reassessing Valuation After Positive Phase 3 HOPE-3 Results for Deramiocel
Capricor Therapeutics (CAPR) has reported positive Phase 3 HOPE-3 data for its Duchenne muscular dystrophy therapy, Deramiocel, leading to a reassessment of its valuation. Despite significant share price gains, the stock is considered 41.6% undervalued by a popular narrative, suggesting a fair value of $44.56 per share based on aggressive growth assumptions. However, its high price-to-book ratio compared to peers indicates potential risks if Deramiocel faces regulatory setbacks.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts
Capricor Therapeutics (NASDAQ:CAPR) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $37.00. Several firms, including HC Wainwright, Oppenheimer, and Piper Sandler, have recently raised their price targets, indicating optimism. Institutional investors own approximately 21.68% of the company's stock, and shares are currently trading up with a market cap of $1.31 billion.
